Ten-Patient Trial: Remarkable Responses in Pediatric Cancers

A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of ge...

Descripción completa

Detalles Bibliográficos
Autor principal: Mardis, Elaine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690083/
https://www.ncbi.nlm.nih.gov/pubmed/37733329
http://dx.doi.org/10.1158/1078-0432.CCR-23-2232
Descripción
Sumario:A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair–based susceptibility. See related article by Das et al., p. 4770

Ejemplares similares